Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Adherium Ltd. ( (AU:ADR) ).
Adherium has extended the closing date of its retail entitlement offer by one week, shifting the deadline from 5 March to 12 March 2026, while keeping the offer price at A$0.003 per new share and all other terms unchanged. The move gives eligible retail shareholders in Australia and New Zealand additional time to assess and participate in the capital raising, potentially supporting a more complete take-up of the offer and shoring up funding alongside the already completed placement and institutional entitlement components.
The revised timetable pushes subsequent milestones, including announcement of retail offer results, settlement, allotment, and commencement of normal trading for the new shares, into mid to late March 2026. Shareholders who have already lodged valid applications are not required to take further action, while eligibility remains limited to retail securityholders on the 18 February 2026 record date, ensuring the capital raising proceeds within the originally defined investor base.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is an Australia-based digital health company focused on respiratory disease management. It develops and commercialises the FDA-cleared Hailie Smartinhaler platform, which combines sensor-enabled inhaler devices with software to monitor and improve medication adherence for patients, positioning the firm in the global digital respiratory management market.
Technical Sentiment Signal: Sell
Current Market Cap: A$13.97M
Learn more about ADR stock on TipRanks’ Stock Analysis page.